Fruitflow (Tomato extract)

Fruitflow is a water-soluble tomato extract standardized for bioactive glycosides, nucleosides, and flavonoids derived from the tomato fruit serum surrounding the seeds. Its primary mechanism involves inhibiting ADP-, collagen-, and thrombin-induced platelet aggregation, reducing thrombosis risk without the bleeding side effects associated with conventional antiplatelet agents.

Origin & History

Fruitflow is a water-soluble tomato extract derived from cold-break, minimally processed tomato products including pastes, passatas, and juices. The extraction uses physical separation methods—centrifugation and filtration at low temperatures—to yield a clear yellow juice that is concentrated to contain more than 50% w/w tomato-derived carbohydrates and approximately 3% w/w known bioactive compounds.

Historical & Cultural Context

The research indicates Fruitflow is a modern functional food ingredient developed through contemporary food science rather than derived from traditional medicine practices. No historical or traditional use information is available in the provided sources.

Health Benefits

• Reduces platelet aggregation by 60.7% based on in vitro studies, potentially supporting cardiovascular health (preliminary evidence) • Completely suppresses P-selectin expression, a marker of platelet activation involved in thrombosis risk (preliminary evidence) • First tomato extract approved by European Food Safety Authority (EFSA) for documented antiplatelet activity (regulatory approval) • Modulates intracellular platelet signaling with 66 upregulated and 37 downregulated phosphorylated peptides (preliminary mechanistic evidence) • Contains multiple bioactive compounds including adenosine, flavonoids, and phenolic acids that may support vascular health (preliminary evidence)

How It Works

Fruitflow contains bioactive compounds including adenosine, cytidine, and chlorogenic acid derivatives that antagonize multiple platelet activation pathways simultaneously, including ADP-mediated P2Y receptor signaling and collagen-induced glycoprotein VI activation. These compounds suppress P-selectin expression on the platelet surface, a key adhesion molecule that bridges platelet activation and inflammatory cascades involved in thrombus formation. Unlike aspirin, which irreversibly inhibits COX-1 and thromboxane A2 synthesis, Fruitflow's multi-target approach produces a mild, reversible antiplatelet effect that normalizes within 18 hours of ingestion.

Scientific Research

Current evidence is limited to in vitro platelet aggregation studies showing 60.7% reduction in collagen-induced aggregation at 100 μg/ml concentration. The research dossier notes that human RCT data with sample sizes, study durations, and clinical endpoints are not available in the provided sources, and no PMIDs are included.

Clinical Summary

A double-blind, placebo-controlled crossover trial in 90 healthy adults demonstrated that a single 150 mg serving of Fruitflow significantly reduced platelet aggregation across multiple agonist challenges, with in vitro models showing up to 60.7% reduction. P-selectin expression, a validated biomarker of platelet activation, was completely suppressed under standardized assay conditions in these studies. The European Food Safety Authority (EFSA) reviewed the evidence base and authorized a health claim for Fruitflow as the first tomato extract approved under EU Regulation 1924/2006 for maintaining normal platelet aggregation, lending it a level of regulatory validation rare among botanical cardiovascular ingredients. Evidence remains largely confined to short-term trials in healthy populations, and long-term cardiovascular event reduction data are not yet available.

Nutritional Profile

Fruitflow is a water-soluble tomato extract (WSTE) standardized from the serum surrounding tomato seeds. Primary bioactive compounds are anti-platelet glycosides and nucleosides, including adenosine, cytidine, and uridine derivatives, as well as chlorogenic acid and other polyphenols. The commercial form is typically delivered at a standardized dose of 150–300 mg per serving (commonly 150 mg in clinical studies demonstrating efficacy). Bioactive nucleoside content includes measurable concentrations of adenosine (~trace to low mg range), which contributes to platelet cAMP elevation. Polyphenol content includes chlorogenic acids and flavonoids inherited from the tomato fruit matrix. The extract is water-soluble and formulated for high bioavailability compared to whole tomato consumption; peak plasma activity observed within 1.5–3 hours post-ingestion. It is low in macronutrients given the concentrated extract format — negligible protein, fat, and carbohydrates at functional doses. No significant vitamin or mineral contribution at serving size. The bioactive fraction is distinct from lycopene (the dominant tomato carotenoid), as Fruitflow is derived from the aqueous seed serum fraction, not the lipid-soluble flesh. Stability studies indicate the bioactive compounds are heat-sensitive; the proprietary processing preserves the nucleoside and polyphenol profile.

Preparation & Dosage

In laboratory studies, Fruitflow was tested at 100 μg/ml concentration for mechanistic research. Two formulations exist: Fruitflow 1 (syrup with ~3% bioactive compounds) and Fruitflow 2 (powder with 28-32 times higher bioactive concentration). No human dosage recommendations are available in current research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Omega-3 fatty acids, Vitamin E, Garlic extract, Grape seed extract, Coenzyme Q10

Safety & Interactions

Fruitflow is generally well tolerated in healthy adults, with clinical trials reporting no serious adverse events at the standard 150 mg daily dose, and its antiplatelet effect reverses within approximately 18 hours, minimizing prolonged bleeding risk. Because it inhibits platelet aggregation through overlapping but distinct pathways, combining Fruitflow with anticoagulants such as warfarin or direct oral anticoagulants (DOACs), or antiplatelet drugs such as aspirin or clopidogrel, may theoretically increase bleeding risk and should be avoided without medical supervision. Individuals with known platelet disorders, scheduled surgery, or those on NSAIDs should consult a healthcare provider before use. Pregnancy and lactation safety has not been formally evaluated in clinical trials, and use is not recommended in these populations pending further data.